[go: up one dir, main page]

SG11201708194WA - Fusion proteins - Google Patents

Fusion proteins

Info

Publication number
SG11201708194WA
SG11201708194WA SG11201708194WA SG11201708194WA SG11201708194WA SG 11201708194W A SG11201708194W A SG 11201708194WA SG 11201708194W A SG11201708194W A SG 11201708194WA SG 11201708194W A SG11201708194W A SG 11201708194WA SG 11201708194W A SG11201708194W A SG 11201708194WA
Authority
SG
Singapore
Prior art keywords
fusion proteins
fusion
proteins
Prior art date
Application number
SG11201708194WA
Other languages
English (en)
Inventor
David Bruce Baldwin
John Michael Beals
Jonathan Wesley Day
Craig Duane Dickinson
Andrew Ihor Korytko
Gregory Alan Lazar
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55953435&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201708194W(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SG11201708194WA publication Critical patent/SG11201708194WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
SG11201708194WA 2015-05-07 2016-04-28 Fusion proteins SG11201708194WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562158079P 2015-05-07 2015-05-07
PCT/US2016/029807 WO2016178905A1 (en) 2015-05-07 2016-04-28 Fusion proteins

Publications (1)

Publication Number Publication Date
SG11201708194WA true SG11201708194WA (en) 2017-11-29

Family

ID=55953435

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201708194WA SG11201708194WA (en) 2015-05-07 2016-04-28 Fusion proteins

Country Status (40)

Country Link
US (5) US9855318B2 (ja)
EP (1) EP3292141B1 (ja)
JP (1) JP6591562B2 (ja)
KR (1) KR102059736B1 (ja)
CN (1) CN107531806B (ja)
AR (1) AR105616A1 (ja)
AU (1) AU2016257659B2 (ja)
CA (1) CA2981102A1 (ja)
CL (1) CL2017002761A1 (ja)
CO (1) CO2017011301A2 (ja)
CR (1) CR20170469A (ja)
CY (1) CY1122929T1 (ja)
DK (1) DK3292141T3 (ja)
DO (1) DOP2017000258A (ja)
EA (1) EA039770B1 (ja)
EC (1) ECSP17073650A (ja)
ES (1) ES2799099T3 (ja)
HR (1) HRP20200503T1 (ja)
IL (1) IL254965B (ja)
JO (1) JO3658B1 (ja)
LT (1) LT3292141T (ja)
MA (1) MA42037B1 (ja)
MD (1) MD3292141T2 (ja)
ME (1) ME03709B (ja)
MX (1) MX388594B (ja)
MY (1) MY183025A (ja)
NZ (1) NZ736470A (ja)
PE (1) PE20180507A1 (ja)
PH (1) PH12017502025B1 (ja)
PL (1) PL3292141T3 (ja)
PT (1) PT3292141T (ja)
RS (1) RS60044B1 (ja)
SG (1) SG11201708194WA (ja)
SI (1) SI3292141T1 (ja)
SV (1) SV2017005548A (ja)
TN (1) TN2018000059A1 (ja)
TW (1) TWI656132B (ja)
UA (1) UA122146C2 (ja)
WO (1) WO2016178905A1 (ja)
ZA (1) ZA201706334B (ja)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11208452B2 (en) 2015-06-02 2021-12-28 Novo Nordisk A/S Insulins with polar recombinant extensions
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
KR102233545B1 (ko) 2016-07-27 2021-03-29 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. 디지털 유체 레벨 센서를 갖는 유체 공급 카트리지용 수평 인터페이스
HRP20211334T1 (hr) * 2016-12-09 2021-11-26 Akston Biosciences Corporation Inzulin-fc fuzije i načini uporabe
TR201703622A1 (tr) * 2017-03-09 2018-09-21 Univ Yeditepe Obezi̇te tedavi̇si̇ i̇çi̇n bi̇r ürün
JP2020513019A (ja) * 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−Ｆｃコンジュゲート
TWI835773B (zh) * 2018-01-26 2024-03-21 美商建南德克公司 組合物及使用方法
EP3810640A1 (en) 2018-06-25 2021-04-28 University of Washington De novo design of potent and selective interleukin mimetics
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
HUE065725T2 (hu) * 2018-06-29 2024-06-28 Akston Biosciences Corp Ultra-hosszú hatású inzulin-FC fúziós fehérjék és alkalmazási eljárások
WO2020074544A1 (en) 2018-10-10 2020-04-16 Novo Nordisk A/S Oligomer extended insulin-fc conjugates and their medical use
EP3883956A1 (en) 2018-11-20 2021-09-29 University of Washington Split interleukin mimetics and their use
WO2020190591A1 (en) * 2019-03-15 2020-09-24 Eli Lilly And Company Preserved formulations
WO2021011827A1 (en) * 2019-07-16 2021-01-21 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
TWI844709B (zh) 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
MX2022004311A (es) 2019-10-15 2022-05-10 Lilly Co Eli Estirpes celulares de mamiferos con deficiencia de lipasa/esterasa modificadas geneticamente de manera recombinante.
EP4073098B1 (en) * 2019-12-19 2023-09-27 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
WO2021188374A2 (en) 2020-03-16 2021-09-23 Neoleukin Therapeutics, Inc. Interleukin-2 receptor βeta (il-2rβ) binding polypeptides
JP2023521706A (ja) 2020-04-07 2023-05-25 ネオロイキン セラピューティクス， インコーポレイテッド アンギオテンシン変換酵素２（ａｃｅ２）のデノボタンパク質デコイ
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
BR112022020486A2 (pt) 2020-04-10 2023-01-17 Akston Biosciences Corp Imunoterapia específica de antígeno para proteínas de fusão de covid-19 e métodos de uso
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US20230272030A1 (en) * 2020-07-24 2023-08-31 Jiangsu Gensciences Inc. Insulin-fc fusion protein and application thereof
CN116723852A (zh) * 2020-12-14 2023-09-08 伊莱利利公司 治疗糖尿病的方法
US11667689B2 (en) 2021-07-23 2023-06-06 Akston Biosciences Corporation Insulin-Fc fusion proteins and methods of use to treat cancer
WO2023044318A2 (en) 2021-09-15 2023-03-23 Neoleukin Therapeutics, Inc. Interleukin-2 receptor βeta (il-2rβ) binding polypeptides
TWI871539B (zh) 2021-11-15 2025-02-01 美商美國禮來大藥廠 可保存之調配物
EP4495143A1 (en) * 2022-03-16 2025-01-22 Beijing Tuo Jie Biopharmaceutical Co. Ltd. Human insulin analogue, and fusion protein thereof and medical use thereof
KR20250004935A (ko) 2022-05-18 2025-01-08 프로토머 테크놀로지스 인크. 방향족 붕소-함유 화합물 및 관련 인슐린 유사체
CN119403824A (zh) 2022-06-23 2025-02-07 赛诺菲 单链胰岛素及其Fc缀合物
WO2024137820A1 (en) * 2022-12-20 2024-06-27 The Board Of Trustees Of The Leland Stanford Junior University Insulin receptor antagonist
CN115894720B (zh) * 2023-01-16 2024-07-09 中国科学院上海药物研究所 一种长效胰岛素-Fc融合蛋白
WO2024229093A1 (en) 2023-05-03 2024-11-07 Eli Lilly And Company Methods and systems for managing diabetes
WO2025059010A1 (en) 2023-09-11 2025-03-20 Eli Lilly And Company Methods and systems for managing diabetes
WO2025061146A1 (zh) * 2023-09-20 2025-03-27 上海迈晋生物医药科技有限公司 一种人胰岛素类似物融合蛋白的药物组合物及其医药用途
WO2025080923A1 (en) 2023-10-13 2025-04-17 Eli Lilly And Company Insulin-fc fusion proteins

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
NZ250844A (en) 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
AU5724996A (en) 1995-05-05 1996-11-21 Eli Lilly And Company Single chain insulin with high bioactivity
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
CA2369839A1 (en) 1999-06-25 2001-01-04 Minimed, Inc. Compositions of insulin and insulin-related peptide for treating diabetes
KR100449454B1 (ko) 2000-10-02 2004-09-21 이현철 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터
CN1483041A (zh) 2000-12-07 2004-03-17 Glp-1融合蛋白
JP2005519041A (ja) 2001-12-20 2005-06-30 イーライ・リリー・アンド・カンパニー 長期作用を備えたインスリン分子
DK1641823T3 (da) 2003-06-12 2011-12-12 Lilly Co Eli GLP-1-analog fusionsproteiner
EP1668419B1 (en) 2003-10-02 2010-07-28 Carl Zeiss SMT AG Projection objective for semiconductor lithography
AU2004295023A1 (en) 2003-12-03 2005-06-16 Novo Nordisk A/S Single-chain insulin
JP2008533100A (ja) 2005-03-18 2008-08-21 ノボ ノルディスク アクティーゼルスカブ Ｐｅｇ化された単鎖インスリン
EP1991575A1 (en) 2006-02-21 2008-11-19 Novo Nordisk A/S Single-chain insulin analogues and pharmaceutical formulations thereof
JP2009530243A (ja) 2006-03-13 2009-08-27 ノボ・ノルデイスク・エー／エス アシル化単鎖インスリン
US20090069215A1 (en) 2006-03-13 2009-03-12 Novo Nordisk A/S Acylated Single Chain Insulin
KR101729986B1 (ko) 2006-09-22 2017-04-25 노보 노르디스크 에이/에스 프로테아제 내성 인슐린 유사체
EP2074140B8 (en) 2006-10-04 2015-10-28 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
WO2008049711A1 (en) 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins
KR101380732B1 (ko) * 2007-05-30 2014-04-10 포항공과대학교 산학협력단 면역글로불린 융합 단백질
KR20100020516A (ko) 2007-07-10 2010-02-22 일라이 릴리 앤드 캄파니 Ｇｌｐ-1-ｆｃ 융합 단백질 제제
ES2618073T3 (es) 2008-03-14 2017-06-20 Novo Nordisk A/S Análogos de insulina estabilizados frente a proteasas
EP2910569B1 (en) * 2008-03-18 2016-10-05 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
CA2722168A1 (en) 2008-04-22 2009-10-29 Case Western Reserve University Isoform-specific insulin analogues
GB0812019D0 (en) 2008-07-02 2008-08-06 Asterion Ltd Insulin
UA101670C2 (ru) 2008-07-23 2013-04-25 Ханми Сайенс Ко., Лтд. Полипептидный комплекс, содержащий непептидильный полимер, который имеет три функциональных конца
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
KR101324828B1 (ko) 2010-06-08 2013-11-01 한미사이언스 주식회사 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체
AU2011268327B2 (en) 2010-06-16 2016-02-25 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
KR20140044305A (ko) 2011-02-09 2014-04-14 글락소스미스클라인 엘엘씨 동결건조된 제제
CN102718870B (zh) * 2011-05-24 2014-04-30 马鞍山中美德康生物科技有限公司 一种胰岛素生物增敏剂及其应用
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
CN102516393B (zh) * 2011-11-30 2017-03-15 北京康明百奥新药研发有限公司 胰岛素模拟肽融合蛋白和突变体及其应用
CN103509118B (zh) * 2012-06-15 2016-03-23 郭怀祖 胰岛素-Fc融合蛋白
US20150111820A1 (en) 2012-07-09 2015-04-23 Novo Nordisk A/S Novel use of insulin derivatives
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
AR092862A1 (es) 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
WO2014052451A2 (en) 2012-09-26 2014-04-03 Indiana University Research And Technology Corporation Insulin analog dimers
MX2015005662A (es) 2012-11-05 2015-08-20 Univ Case Western Reserve Analogos de insulina de una sola cadena de larga accion.
AU2014221534B2 (en) 2013-02-26 2018-06-28 Hanmi Pharm. Co., Ltd. Site-specific insulin conjugate
CN105026423A (zh) * 2013-03-14 2015-11-04 瑞泽恩制药公司 爱帕琳融合蛋白和其用途
PL3055325T3 (pl) 2013-10-07 2018-06-29 Novo Nordisk A/S Nowa pochodna analogu insuliny
MX369656B (es) 2014-01-20 2019-11-15 Hanmi Pharm Ind Co Ltd Insulina de accion prolongada y uso de la misma.
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
KR20160001391A (ko) 2014-06-27 2016-01-06 한미약품 주식회사 신규한 지속형 인슐린 아날로그 결합체 및 이의 용도
KR20160007295A (ko) 2014-07-11 2016-01-20 한미약품 주식회사 인슐린 아날로그
US10392429B2 (en) 2014-10-06 2019-08-27 Case Western Reserve University Biphasic single-chain insulin analogues
KR102049647B1 (ko) 2014-11-21 2019-11-29 머크 샤프 앤드 돔 코포레이션 인슐린 수용체 부분 효능제
WO2016133372A2 (ko) 2015-02-17 2016-08-25 한미약품 주식회사 지속형 인슐린 또는 이의 아날로그 결합체
CN110134210A (zh) 2019-04-16 2019-08-16 深圳市国鑫恒宇科技有限公司 一种服务器一体机的温度控制方法、系统、装置及存储介质

Also Published As

Publication number Publication date
KR102059736B1 (ko) 2019-12-26
PH12017502025A1 (en) 2018-04-02
US20160324932A1 (en) 2016-11-10
HK1244019A1 (en) 2018-07-27
NZ736470A (en) 2019-04-26
JP6591562B2 (ja) 2019-10-16
CO2017011301A2 (es) 2018-03-20
US20220211818A1 (en) 2022-07-07
DK3292141T3 (da) 2020-04-20
CL2017002761A1 (es) 2018-05-18
CN107531806A (zh) 2018-01-02
SV2017005548A (es) 2018-04-24
ZA201706334B (en) 2020-01-29
EP3292141B1 (en) 2020-02-12
US20200390865A1 (en) 2020-12-17
MA42037B1 (fr) 2020-03-31
US11253574B2 (en) 2022-02-22
US12059452B2 (en) 2024-08-13
TW201712029A (zh) 2017-04-01
CN107531806B (zh) 2022-06-07
PT3292141T (pt) 2020-04-22
WO2016178905A1 (en) 2016-11-10
ME03709B (me) 2021-01-20
JP2018515088A (ja) 2018-06-14
BR112017020502A2 (pt) 2018-07-03
TWI656132B (zh) 2019-04-11
MD3292141T2 (ro) 2020-07-31
US20180177851A1 (en) 2018-06-28
TN2018000059A1 (en) 2019-07-08
US20250032588A1 (en) 2025-01-30
DOP2017000258A (es) 2017-12-31
ECSP17073650A (es) 2018-02-28
EA039770B1 (ru) 2022-03-11
RS60044B1 (sr) 2020-04-30
AU2016257659A1 (en) 2017-10-12
JO3658B1 (ar) 2020-08-27
PE20180507A1 (es) 2018-03-09
IL254965B (en) 2021-03-25
HRP20200503T1 (hr) 2020-06-26
MX388594B (es) 2025-03-20
KR20170134614A (ko) 2017-12-06
IL254965A0 (en) 2017-12-31
LT3292141T (lt) 2020-03-25
MX2017014284A (es) 2018-03-23
US9855318B2 (en) 2018-01-02
CA2981102A1 (en) 2016-11-10
SI3292141T1 (sl) 2020-04-30
CY1122929T1 (el) 2021-10-29
PH12017502025B1 (en) 2018-04-02
AU2016257659B2 (en) 2018-08-09
AR105616A1 (es) 2017-10-25
MY183025A (en) 2021-02-07
EP3292141A1 (en) 2018-03-14
EA201792199A1 (ru) 2018-03-30
UA122146C2 (uk) 2020-09-25
US10709766B2 (en) 2020-07-14
PL3292141T3 (pl) 2020-06-29
CR20170469A (es) 2017-11-14
ES2799099T3 (es) 2020-12-14

Similar Documents

Publication Publication Date Title
IL254965B (en) fusion proteins
ZA201701810B (en) Sirp-alpha immunoglobulin fusion proteins
GB201509413D0 (en) Fusion protein
IL246355A0 (en) p97–ids fused proteins
GB201504691D0 (en) Fusion protein
ZA202003845B (en) Fusion proteins
GB201515745D0 (en) Proteins
GB201511787D0 (en) Proteins
ZA201606327B (en) Uti fusion proteins
GB201503218D0 (en) Particles comprising fusion proteins
GB201513033D0 (en) Proteins
ZA201801394B (en) Fusion protein
SG11201606501PA (en) Nanobody-fluorescent protein fusion
EP3649159C0 (en) FUSION PROTEIN
GB201602850D0 (en) Fusion proteins
GB201712792D0 (en) Fusion protein
IL244857A0 (en) A fusion protein of acetylcholinesterase and the fc region
GB201713537D0 (en) Fusion Polypeptide
GB201503789D0 (en) Fusion polypeptide
GB201515744D0 (en) Proteins
GB201503778D0 (en) Proteins